Streetwise Articles



Analyst: G1 Minimizes the Carnage of Chemotherapy
Source: Streetwise Reports  (7/1/20)
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. More >


'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug
Source: Streetwise Reports  (7/1/20)
Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. More >


Life Sciences Firm Submits IND Application to FDA for Phase 3 COVID-19 Study
Source: Streetwise Reports  (7/1/20)
Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2. More >


Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study
Source: Streetwise Reports  (7/1/20)
Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. More >


Biopharma's Multinational COVID-19 Study Receives US Ethics Approval
Source: Streetwise Reports  (6/30/20)
Algernon Pharmaceuticals is seeking approved participation from Australia, Romania and the Philippines as well. More >


Life Sciences Firm Gains Approval to Sell Non-Antibiotic Livestock Feed Additive in Brazil
Source: Streetwise Reports  (6/25/20)
Avivagen reported it received approval for use of OxC-beta™ Livestock in Brazil and it has signed an agreement with a São Paulo company for distribution. More >


Vaxart Shares Rise 95% After Signing Agreement for Oral Tablet COVID-19 Vaccine
Source: Streetwise Reports  (6/25/20)
Shares of Vaxart Inc. nearly doubled after the company reported that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow to enable production of a billion or more tablet COVID-19 vaccine doses annually. More >


Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity
Source: Streetwise Reports  (6/24/20)
These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. More >


Telemedicine Firm to Acquire Majority Interest in Ontario Clinic
Source: Streetwise Reports  (6/23/20)
With this transaction, CloudMD Software & Services expands its size and reach. More >


Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines
Source: Streetwise Reports  (6/23/20)
Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas. More >


Invitae Corp. Enters into Definitive Agreement to Acquire ArcherDX
Source: Streetwise Reports  (6/22/20)
Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. More >


FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients
Source: Streetwise Reports  (6/19/20)
Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. More >


Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie
Source: Streetwise Reports  (6/18/20)
Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. More >


Regenerative Medicine Firm Reports Early Results from COVID-19 Trials
Source: Streetwise Reports  (6/17/20)
Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. More >


Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment
Source: Streetwise Reports  (6/17/20)
The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. More >


Biotech Makes 'Significant Progress' Creating Highly Accurate COVID-19 Antibody Test
Source: Streetwise Reports  (6/17/20)
ProMIS Neurosciences states that the current version of the ProMIS-BCNI assay achieves 99.9% sensitivity and 99.5% specificity for SARS CoV-2, the coronavirus causing COVID-19. More >


Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results
Source: Streetwise Reports  (6/16/20)
Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. More >


Digital Health Company Growth Continues with Acquisition of BC Medical Clinic
Source: Streetwise Reports  (6/15/20)
CloudMD reported that it has signed a binding agreement to acquire a British Columbia medical clinic with 12 on-staff physicians in a cash and stock deal valued at CA$700,000. More >


Life Sciences Firm Expands Collaboration Efforts with Major U.S. University to Develop Psilocybin-Based Medicines
Source: Streetwise Reports  (6/15/20)
Revive Therapeutics Ltd. reported it has expanded its research partnership for novel formulation development and clinical research of psilocybin with the University of Wisconsin-Madison. More >


Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study
Source: Streetwise Reports  (6/15/20)
Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19. More >


Reata Pharma Announces $350 Million Strategic Investment from Blackstone Life Sciences
Source: Streetwise Reports  (6/11/20)
Shares of Reata Pharmaceuticals traded 30% higher after reporting that Blackstone Life Sciences will invest $350 million in the company to advance bardoxolone methyl as a potential therapy for Alport syndrome and other rare and serious chronic kidney diseases. More >


Life Sciences Firm Pursues Phase 3 COVID-19 Treatment Trial in Canada
Source: Streetwise Reports  (6/10/20)
Revive Therapeutics met with Health Canada to discuss how best to proceed. More >


Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody
Source: Streetwise Reports  (6/10/20)
Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. More >


Coverage Initiated on Company at 'Forefront of the Telehealth Revolution'
Source: Streetwise Reports  (6/8/20)
A review of CloudMD Software & Services and the reasons why it makes a compelling investment are provided in a Beacon Securities report. More >


Enochian Shares Trade Up 50% upon Concluding FDA Meeting for Potential HIV Cure
Source: Streetwise Reports  (6/8/20)
Shares of Enochian Biosciences reached a new 52-week high after the company reported that it successfully completed its FDA INTERACT meeting for ENOB-HV-01, a potential cure for HIV. More >


Showing Results: 1 to 25 of 1516 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts